Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, Galapagos Extend Functional Genomics Deal

NEW YORK, Sept 10 – Incyte Genomics said Monday it had extended a deal with Galapagos Genomics of Mechelen, Belgium to further develop an adenoviral library for Incyte’s in-house drug development program.

Under the terms of the agreement, the companies will work to characterize the function of proteins Incyte is studying in its drug discovery and target validation programs.

The deal is an extension of a collaboration announced last year in which the companies agreed to develop and commercialize a recombinant adenoviral library for gene function discovery and validation. During the first phase of the collaboration, which included 1,500 genes from Incyte’s database, the companies tested the genes against several disease model cell lines. 

Now, Galapagos will construct a custom adenoviral library with genes relevant to Incyte's in house drug target discovery and validation efforts. Incyte will then further validate the studies using the viruses Galapagos produces.

"We are very pleased with the progress of the current collaboration," Roy Whitfield, CEO of Incyte, said in a statement.

"The Galapagos' adenoviral technology has great value for drug target validation programs and the expansion of the collaboration toward our proprietary therapeutic programs is therefore a logical extension," he added. 

Recombinant adenoviral technology is considered to be a cost-effective method that directly associates human genes with phenotypic changes such as morphology, motility, proliferation, differentiation, signal transduction, enzyme, and transport activity, Incyte said.

Financial terms of the latest deal were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.